91103-37-6

Usage

Uses

Used in Organic Synthesis:
(S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate is used as a reagent for the protection of primary amines during chemical reactions. Its ability to shield amines from unwanted side reactions is crucial for the selective synthesis of desired compounds.
Used as a Precursor in Organic Chemistry:
(S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate also serves as a precursor for the synthesis of other organic compounds, contributing to the creation of a wide range of chemical products and intermediates in various chemical processes.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (S)-tert-butyl 1-hydroxybut-3-en-2-ylcarbamate may be utilized in the development of new drugs, given its potential to form complex organic molecules that could have medicinal properties.
Used in Research and Development:
Its applications extend to research and development settings where new methods and compounds are explored, taking advantage of its reactivity and stability to innovate in chemical synthesis techniques.

Upstream product

• 2488-15-5 N-t-butoxycarbonyl-L-methionine 
• 115378-31-9 N-Boc-2,2-dimethyl-4-ethenyloxazolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 313995-40-3 (2S)-1-hydroxybut-3-en-2-methylpyrrole-2-carboxylate 
• 271260-82-3 (S)-2-(N-tert-butoxycarbonylamino)-3-butenyl-acetate 
• 136374-47-5 (S)-N-(1-hydroxymethyl-3-methanesulfinylpropyl)carbamic acid t-butyl ester 
• 133625-87-3 tert-butyl (4S)-2,2-dimethyl-4-vinyl-1,3-oxazolidine-3-carboxylate 
• 2065-66-9 methyl-triphenylphosphonium iodide 
• 115148-32-8 (S)-3-(4-methoxyphenyl)-4-vinyloxazolidin-2-one 
• 930-22-3 epoxybutene 
• 88000-67-3 tert-butyl benzoylimidocarboxylate 
• 913344-40-8 tert-butyl N-formyl carbamate 
• 318469-73-7 (2E)-4-hydroxybut-2-en-1-yl methyl carbonate 
• 117609-25-3 (S)-(+)-2-amino-1-butanol 

Downstream Products

• 133625-87-3 tert-butyl (4S)-2,2-dimethyl-4-vinyl-1,3-oxazolidine-3-carboxylate 
• 354153-37-0 1,1-dimethylethyl [(1S)-1-({[(1,1-dimethylethyl)(diphenyl)silyl]oxy}methyl)prop-2-en-1-yl]carbamate 
• 91028-39-6 L-2-<<(tert-Butyloxy)carbonyl>amino>-3-butenoic Acid 
• 917365-70-9 C₃₆H₃₉BrN₄O₁₀S₂ 
• 917365-57-2 C₂₆H₂₉BrN₂O₆S 
• 1315454-60-4 C₁₇H₂₅NO₅ 
• 106074-85-5 (2R,3R)-2-(tert-butoxycarbonyl)amino-3-(tetrahydropyranyl)oxy-4-<4-(tert-butyldimethylsilyl)oxy>phenylbutyl acetate 

Relevant academic research and scientific papers

Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors

An alternative medicinal chemistry approach was conducted on Bruton's tyrosine kinase (BTK) inhibitor 1 (ibrutinib) by merging the pyrazolo[3,4-d]pyrimidine component into a tricyclic skeleton. Two types of compounds were prepared, and their biochemical activities on BTK as well as stereochemistry effects were determined. Structural optimization focusing on the reactive binding group to BTK Cys481 and on the metabolic site guided by metabolic study were conducted. 7S was identified as the most potent showing an IC50 value of 0.4 nM against BTK and 16 nM against BTK-dependent TMD8 cells. Compared to 1, 7S was slightly more selective with strong inhibition on the B-cell receptor signaling pathway. In a TMD8 cell-derived animal xenograft model, 7S showed a relative tumor volume of 5.3 at 15 mg/kg QD dosage that was more efficacious than 1 (RTV 6.6) at a higher dose of 25 mg/kg QD. All these results suggest 7S as a new BTK inhibitor worthy of further profiling.

MACROCYCLIC LRRK2 KINASE INHIBITORS

The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.

Enantioselective Formal Synthesis of Nectrisine Using a Palladium-Catalyzed Asymmetric Allylic Amination and Cross-Metathesis as Key Steps

A formal enantioselective synthesis of nectrisine, a potent α-glucosidase inhibitor, was carried out starting from butadiene monoepoxide through a synthetic sequence involving enantioselective allylic substitution, cross-metathesis, dihydroxylation, and cyclization.

SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS

This application relates to methods of increasing survival or progression-free survival in a patient with a solid tumor, wherein the patient has an elevated serum concentration of C-reactive protein (CRP), by administering a JAK inhibitor or an inhibitor of IL-6 signaling to the patient, as well as methods of predicting survival benefit in these patients from such therapy.

TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR

This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3Kδ.

BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS

This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.

TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1

This invention relates to JAK selective inhibitors for use in treatment of chronic neutrophilic leukemia and atypical chronic myeloid leukemia in patients.

TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS

The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Development of a flexible strategy towards FR900482 and the mitomycins

FR900482 and the mitomycins are two intriguing classes of alkaloid natural products that have analogous biological mechanisms and obvious structural similarity. Both classes possess potent anticancer activity, a feature that has led to their investigation

Enantioselective iridium-catalyzed allylic aminations of allylic carbonates with functionalized side chains. Asymmetric total synthesis of (S)-vigabatrin

Indium-catalyzed aminations of allylic carbonates containing a variety of O-functional groups have been explored. High degrees of regio- as well as enantioselectivity were achieved with diacylamides under salt-free conditions and with arylamines. The results allowed the antiepilepsy drug (5)-vigabatrin to be prepared via a very short route.